Holen Sie sich die Stockscreener-App
31.68
3.21%
-1.05
Vorhandelsmarkt:
31.66
-0.02
-0.06%
Schlusskurs vom Vortag:
$32.73
Offen:
$33.45
24-Stunden-Volumen:
8.25M
Relative Volume:
0.38
Marktkapitalisierung:
$7.33B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
60.68
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-14.77%
1M Leistung:
-5.55%
6M Leistung:
+3.80%
1J Leistung:
-36.65%
1-Tages-Spanne:
$31.45
$34.00
1-Wochen-Bereich:
$31.45
$37.70
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
31.68 | 7.33B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.87 | 53.87B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.85 | 43.38B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.15 | 35.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.19 | 31.10B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.07 | 26.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers stands to gain if the FDA loosens restrictions on peptides - Reuters
Hims & Hers Health Inc (HIMS) Shares Fall 3.2% -- What GF Score of 83 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
The FDA Is About to Weigh in on the Great Peptide Debate - inc.com
Form 144 Hims & Hers Health For: 22 July By Investing.com - Investing.com Canada
Hims & Hers Health, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
HIMS Sees Surge in App Downloads Amid Peptide Opportunity - GuruFocus
$Hims & Hers Health (HIMS.US)$ 24th July is the key peptide hearing? - Moomoo
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed ‘More Qualified And Less Conflicted’ - Stocktwits
Lobbying Update: $290,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Hims & Hers stock analysis: growth story meets credibility crisis ahead of FDA catalyst - Investing.com Canada
Hims & Hers Health Stock Short Interest Falls to 31.82% - Quiver Quantitative
HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide Meeting - Yahoo Finance
Hims & Hers Chief Accounting Officer Irene Becklund to Depart After Seven Years - citybiz
Technical Reactions to HIMS Trends in Macro Strategies - Stock Traders Daily
HIMS Announces Departure of Chief Accounting Officer Irene Beckl - GuruFocus
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company - 01net
Hims & Hers Health Announces Accounting Officer Resignation - TipRanks
HIMS: Leadership Change as Chief Accounting Officer Steps Down - GuruFocus
Hims & Hers Health Chief Accounting Officer to Step Down - Moomoo
Hims & Hers Health: CFO Yemi Okupe Will Assume Responsibilities of CAO During Search for Permanent CAO >HIMS - Moomoo
Hims & Hers Health Options Spot-On: On July 17th, 114.43K Contracts Were Traded, With 1.02 Million Open Interest - Moomoo
Hims & Hers chief accounting officer to depart in October - Investing.com
Hims & Hers chief accounting officer to depart in October By Investing.com - Investing.com Canada
Hims & Hers Health (NYSE: HIMS) plans CAO Becklund exit - Stock Titan
3 Reasons HIMS Has Explosive Upside Potential - Yahoo Finance
Why Hims & Hers Health (HIMS) Stock Is Down Today - Quiver Quantitative
Why Is Hims & Hers Health (NYSE:HIMS) Scaling Virtual Care Services? - Kalkine Media
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Hims & Hers Health Inc (CHIX:82Wd) Stock Price, Trades & News - GuruFocus
Hims & Hers Health (NYSE:HIMS): What Is Driving Attention? - Kalkine Media
Hims & Hers Health Options Spot-On: On July 16th, 98,408 Contracts Were Traded, With 998.73K Open Interest - Moomoo
This Trade Offers Two Ways To Profit From Hims & Hers Stock - Investor's Business Daily
2026-07-16 | Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NYSE:HIMS | Press Release - Stockhouse
Breakout attempt at $39.02 resistance. Can Hims & Hers Health stock extend gains? - Traders Union
A Look at Hims & Hers Health Inc (HIMS) After 5.8% Gain -- GF Va - GuruFocus
Law firm investigates Hims & Hers for allegedly sharing users' private health data without consent. - Pluang
Lowey Dannenberg, P.C. Investigates Hims & Hers Health, Inc. for Alleged Tracking of User Data - GlobeNewswire
Lowey Dannenberg, P.C. Investigates Hims & Hers Health, Inc. for Alleged Tracking of User Data - GlobeNewswire Inc.
Why is Hims & Hers Health stock up 6.1% today? - Traders Union
Hims & Hers Health shares gain more than 5% after price action confirms trend alignment above key moving averages - Traders Union
Why is Hims & Hers Health stock up today? Resistance test in focus for HIMS - Traders Union
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers to announce Q2 2026 results on August 10 - scanx.trade
Is most-watched stock Hims & Hers Health, Inc. (HIMS) worth betting on now? - MSN
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026 - HIMS Investor Relations
Hims & Hers schedules Aug. 10 call on latest health platform results - Stock Titan
HIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meeting - Stocktwits
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):